XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: An economic analysis

Current Medical Research and Opinion

Volumn 25, Issue 3, 2009, Pages 797-805

  Maniadakis, Nikos ^a   Fragoulakis, Vasilios ^b   Pectasides, Dimitrios ^c   Fountzilas, George ^d  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b Social Insurance Institute   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Capecitabine; Colorectal cancer; Economics; FOLFOX; XELOX

Indexed keywords

AMIKACIN; CALCIUM; CAPECITABINE; CEFTAZIDIME; CEFTRIAXONE; CLINDAMYCIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MAGNESIUM; METRONIDAZOLE; OXALIPLATIN; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEICOPLANIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BOOTSTRAPPING; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; EVENING DOSAGE; FEMALE; GREECE; HEALTH CARE COST; HIGH RISK PATIENT; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH SERVICE; PRODUCTIVITY; STATISTICAL ANALYSIS; SURVIVAL RATE; TRAVEL;

EID: 67149118427     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902719117     Document Type: Article

References (56)

1. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. Lyon, France: International Agency for Research on Cancer Press, 2007. Available at: http://www-dep.iarc.fr/ [Last accessed 6 September 2008]
2. Benson AB. Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm 2007;13:S5-S18 (Pubitemid 47605378)
3. Global burden of disease estimates. Geneva: World Health Organization, 2007. Available at: http://www.who.int [Last accessed 6 September 2008]
4. Cancer trends progress report - 2007 update. Bethesda: National Cancer Institute, National Institutes of Health, 2008. Available at: http://progressreport.cancer.gov [Last accessed 6 September 2008]
5. Colon and rectum. In: American Joint Committee on Cancer. AJCC Cancer Staging Manual, 5th edn. Philadelphia: Lippincott-Raven, 1997
6. Obrand DI, Goedon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997;40:15-24 (Pubitemid 27056393)
7. Kohne CH, Schoffski P, Wilke H, et al. Effective biomodulation by leukovorin of high dose infusion: results of a randomised trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418-426
8. Midgley RS, Kerr DJ, et al. Systematic adjuvant chemotherapy for colorectal cancer. In: Bleiberg H, Rougier P, Wilke HJ, eds. Management of Colorectal Cancer. London: Martin Dunitz, 1998
9. IMPACT investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International multicentre pooled analysis of B2 colon cancer trials (IMPACT B2) investigators. J Clin Oncol 1999;17:1356-1363
10. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:1349-1355 (Pubitemid 29220839)
11. Van Cutsem E, Dicato M, Wils J, et al. Adjuvant treatment of colorectal cancer. Current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001. Eur J Cancer 2002;38:1429-1436 (Pubitemid 34756394)
12. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 2002;94:2766-2792
13. Grothey A, Kellerman L, Schmoll HJ. Deficits on management of patients with colorectal carcinoma in Germany: results of multi-center documentation of therapy algorithms. Med Klin (Munich) 2002;97:270-277 (Pubitemid 34534787)
14. Hensley AS, Ulcickas YM, Jankowski M, et al. Stage III colon cancer in the elderly: adjuvant therapy and survival. Prog Proc Am Soc Clin Oncol 2003;22:748
15. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281 (Pubitemid 28342121)
16. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-297 (Pubitemid 30151522)
17. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised cross over trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-358 (Pubitemid 34121962)
18. Liu G, Fransen E, Fitch MI, et al. Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115 (Pubitemid 27021524)
19. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as firstline treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292 (Pubitemid 32366981)
20. Comella P. A review of the role of capecitabine in the treatment of colorectal cancer. Ther Clin Risk Manag 2007;3:421-431 (Pubitemid 47214982)
21. Comella P, Casaretti R, Sandomenico C, et al. Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence. Drugs 2008;68:949-961 (Pubitemid 351652923)
22. Gramont A, Tournigand C, André T, et al. Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol 2007;34:S37-40 (Pubitemid 46590359)
23. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007;25:102-109 (Pubitemid 350003057)
24. Pandor A, Eggington S, Paisley S, et al. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Health Technol Assess 2006;10:1-185 (Pubitemid 44896104)
25. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006;94:1122-1129
26. Lamberti C, Sauerbruch T, Glasmacher A. Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in people with resected stage III colon cancer. Cancer Treat Rev 2005;31:648-652 (Pubitemid 41662892)
27. Glen H, Cassidy J. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial. Expert Rev Anticancer Ther 2008;8:547-551 (Pubitemid 351818349)
28. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704 (Pubitemid 41007824)
29. Reddy GK. Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in dukes C colon cancer: results from the X-ACT trial. Clin Colorectal Cancer 2004;4:87-88 (Pubitemid 39199247)
30. Scheithauer W, McKendrick J, Begbie S, et al. X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003;14:1735-1743
31. Chua YJ, Zalcberg JR. Progress and challenges in the adjuvant treatment of stage II and III colon cancers. Expert Rev Anticancer Ther 2008;8:595-604 (Pubitemid 351818354)
32. Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol 2007;3:281-294 (Pubitemid 47316043)
33. Capecitabine and oxaliplatine in the adjuvant treatment of stage III (Dukes' C) colon cancer. National Institute of Health and Clinical Excellence, Technology Appraisal Guidance 100, April 2006
34. Pectasides D, Papakostas P, Psirri A. A phase III randomised clinical trial evaluating 5-FU/LV with oxaliplatin (FOLFOX6) relative to the combination of capecitabine with oxaliplatin (XELOX) as adjuvant therapy for patients with colorectal cancer recently admitted to surgery, as stage B2 (high risk) and C according to Duke's. Hellenic Cooperative Oncology Group, Protocol Number HE6C05 2005, 1-38
35. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005;8:521-533 (Pubitemid 41727304)
36. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK, 1997.
37. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York, USA, 1996
38. Maniadakis N, Pallis A, Fragoulakis V, et al. Economic analysis of a multicentre, randomized phase III trial comparing Folfoxiri with Folfiri in patients with metastatic colorectal cancer in Greece. Curr Med Res Opin 2007;23:2251-2257 (Pubitemid 350246611)
39. Fountzilas G, Kalofonos HP, Dafni U, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004;15:1517-1526 (Pubitemid 39409743)
40. Lees M, Aristides M, Maniadakis N, et al. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002;20:325-337 (Pubitemid 34569366)
41. Aristides M, Lees M, Botwood N, et al. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. Eur J Health Econ 2003;4:216-221 (Pubitemid 37247974)
42. Schiller J, Tilden D, Aristides M, et al. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 2004;43:101-112 (Pubitemid 38096299)
43. Fountzilas G, Papakostas P, Dafni U, et al. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2006;17:1560-1567
44. Maniadakis N, Fragoulakis V, Pallis A, et al. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece. Lung Cancer 2007;58:275-281 (Pubitemid 47520631)
45. Chu E, Cartwright TH. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer. J Clin Oncol 2008;26:2224-2226
46. Cassidy J, Schmoll HJ, Van Cutsem E. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 2008;26:2226-2227
47. Douillard JY, Tilleul P, Ychou M, et al. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. Oncology 2007;72:248-254
48. Jansman FG, Postma MJ, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 2007;25:537-562 (Pubitemid 47048039)
49. Twelves CJ. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and costeffectiveness. Clin Colorectal Cancer 2006;6:278-287 (Pubitemid 46157477)
50. Eggington S, Tappenden P, Pandor A, et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer 2006;95:1195-1201 (Pubitemid 44658483)
51. Hieke K, Kleeberg UR, Stauch M, et al. Costs of treatment of colorectal cancer in different settings in Germany. Eur J Health Econ 2004;5:270-273 (Pubitemid 39382527)
52. Grothey A, Kleeberg UR, Stauch M, et al. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds. Z Gastroenterol 2005;43:155-161 (Pubitemid 40332907)
53. Jansman FG, Postma MJ, van Hartskamp D, et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 2004;26:579-589 (Pubitemid 38586459)
54. Jones L, Hawkins N, Westwood M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. Health Technol Assess 2004;8:1-143 (Pubitemid 38279465)
55. Takeda AL, Jones J, Loveman E, et al. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-62 (Pubitemid 46900049)
56. Ward S, Kaltenthaler E, Cowan J, et al. Clinical and costeffectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003;7:1-93 (Pubitemid 37451838)